FDA Final Guidance Includes Reporting Scenarios for Cell- and Tissue-Based Products

Drug Industry Daily
The FDA finalized its 2015 guidance on reporting deviations for human cells, tissues and cellular and tissue-based products, also known as HCT/Ps, offering recommendations for complying with federal reporting requirements and listing the most frequent reports received by CBER.

To View This Article:


Subscribe To Drug Industry Daily